The US Food and Drug Administration (FDA) has said Roche can resume enrolment for a phase three Avastin trial after cases of clinical congestive heart failure (CHF) caused it to be suspended.

The trial is evaluating Avastin in early-stage HER2-negative breast cancer but was stopped in September after six cases of CHF were reported.

The trial (E5103) began enrolment in November 2007 and has 3,487 of the total 4,950 patients already enrolled, Roche said.